angiotensin II receptor blocker


Also found in: Dictionary, Acronyms.

angiotensin II receptor blocker

a drug that binds with angiotensin receptors, preventing endogenous angiotensin II from acting on them and thus reducing the vasoconstriction and sodium retention usually induced by that agonist.

The renin-angiotensin-aldosterone system regulates blood pressure and electrolyte balance. Angiotensin II is a potent vasoconstrictor and neurotransmitter that raises peripheral vascular resistance, induces aldosterone secretion by the adrenal cortices and hence sodium retention, and promotes endothelial dysfunction and the growth and proliferation of vascular smooth muscle. Because angiotensin II plays a pivotal role in the pathogenesis of essential hypertension, congestive heart failure, and diabetic nephropathy, drugs that block its production or action are useful in these and other disorders. Angiotensin receptor blockers (ARBs) in current use are nonpeptides that selectively inhibit the AT1 receptor. In essential hypertension, ARBs have the potential for achieving broader control than angiotensin-converting enzyme (ACE) inhibitors because angiotensin II is generated in tissues, particularly diseased tissues, by enzymes besides ACE. ARBs have been shown to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH), to reverse LVH in such patients, and slow the progression of diabetic nephropathy in those with Type 2 diabetes mellitus and hypertension. ARBs are safe and well tolerated. Unlike ACE inhibitors, they do not inhibit the degradation of bradykinin and hence do not cause cough as a side-effect. Currently, they are approved by the U.S. Food and Drug Administration only for the treatment of hypertension and, in those intolerant of ACE inhibitors, of heart failure. The generic names of angiotensin II receptor blockers end in -sartan, which is derived from the phrase selective angiotensin receptor antagonist.

angiotensin II receptor blocker

n. Abbr. ARB
Any of a class of drugs that reduce peripheral vascular resistance by inhibiting the action of the vasoconstrictor angiotensin II, used in the treatment of hypertension, heart failure, and other cardiovascular disorders. Also called angiotensin receptor blocker, angiotensin II receptor antagonist.

an·gi·o·ten·sin II re·cep·tor block·er

(ARB) (an'jē-ō-ten'sin rĕ-sep'tŏr blok'ĕr)
A drug that binds with angiotensin receptors, preventing endogenous angiotensin II from acting on them and thus reducing the vasoconstriction and sodium retention usually induced by that agonist; used to treat hypertension.
References in periodicals archive ?
In addition, nonsteroidal anti-inflammatory medications (like Aleve or Motrin) and aspirin cause the body to retain sodium and water, which can decrease the effectiveness of ACE inhibitors, angiotensin II receptor blockers and warfarin.
SAN ANTONIO -- The discovery that the angiotensin II receptor blocker telmisartan also acts as a partial agonist of peroxisome proliferator-activated receptor-[gamma] makes it a uniquely promising candidate for the treatment of metabolic syndrome and prevention of type 2 diabetes and cardiovascular disease, Dr.
Bigazzi and his associates evaluated 68 patients treated with an ACE inhibitor or an angiotensin II receptor blocker (ARB) alone (group 1), 68 patients treated with a combination of ACE inhibitors and ARBs (group 2); and 68 patients who received a statin and spironolactone 25 mg/day in addition to ACE inhibitors and ARBs (group 3).
The study is testing the hypothesis that the angiotensin II receptor blocker irbesartan is superior to placebo when added to other antihypertensive agents in patients with atrial fibrillation, noted Dr.
Theoretical considerations suggest that an ACE inhibitor along with an angiotensin II receptor blocker (ARB) should also work, but studies have not shown enhanced blood pressure reduction, although the combination does result in significant reduction in proteinuria.
Most nondiabetologists will probably be surprised to learn that it's an angiotensin II receptor blocker (ARB), according to American Diabetes Association's treatment guidelines.
Furthermore, what is the value of doing annual microevaluations in a diabetic who is already on an ACE inhibitor or angiotensin II receptor blocker, or if that patient has already once demonstrated the condition?
White Patients African American White Treatment (n = 22,706) (n = 30,629) ACE inhibitor 49% 45% Angiotensin II receptor blocker 12% 10% [Beta]-Blockers or [alpha]-, [Beta]-blockers 31% 36% Calcium channel blocker 49% 36% Diuretic treatment 59% 48% Source: Dr.
Results from Val-MARC (Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hsCRP) also showed that valsartan's effect on C-reactive protein (CRP) was independent of blood pressure reduction, suggesting that a pleiotropic, anti-inflammatory effect by this angiotensin II receptor blocker (ARB) might have produced the result.
All patients with diabetes and hypertension should receive an ACE inhibitor or an angiotensin II receptor blocker as one component of their therapy.
Most non-diabetologists will probably be surprised to learn that it's an angiotensin II receptor blocker (ARB), according to American Diabetes Association's treatment guidelines.
Teveten, launched in 1998 by SmithKline Beecham (now GSK) and acquired by Biovail in 2002, is an angiotensin II receptor blocker (ARB) that lowers blood pressure by its effects on the renin-angiotensin-aldosterone system.

Full browser ?